Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Peer-reviewed paperarXiv

Empirical Stability Analysis of Kolmogorov-Arnold Networks in Hard-Constrained Recurrent Physics-Informed Discovery

View original at arxiv.org
{ "id": "2602.09988v1", "url": "http://arxiv.org/abs/2602.09988v1", "title": "Empirical Stability Analysis of Kolmogorov-Arnold Networks in Hard-Constrained Recurrent Physics-Informed Discovery", "summary": "We investigate the integration of Kolmogorov-Arnold Networks (KANs) into hard-constrained recurrent physics-info…
Opening lines of the source · arXiv · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • A shallow KAN can exactly represent any univariate polynomial with sufficient spline resolution

    80% confidence
  • Empirical challenges highlight limitations of the additive inductive bias in the original KAN formulation for state coupling

    80% confidence
  • Small KANs are competitive on univariate polynomial residuals but exhibit severe hyperparameter fragility, instability in deeper configurations, and consistent failure on multiplicative terms

    80% confidence
  • KANs would enable efficient recovery of unknown terms compared to MLPs in hard-constrained recurrent physics-informed architectures

    80% confidence
  • The primary bottleneck in recurrent KAN integration is the optimization stability of the composition, not the symbolic extraction process itself

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com